IP Library › Granted Patent US 12,440,510
Granted Patent B2
US 12,440,510 · App. 18/654,457 · Granted Oct 14, 2025

Use of chondroitin sulfate for relieving ocular pain

Inventors: Richard L. Lindstrom (Wayzata, MN); Kamran Hosseini (Pleasanton, CA); Lyle Bowman (Pleasanton, CA)
Assignee: Surface Ophthalmics, Inc.
A61K31/737A61K9/0048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,510
App. No.
18/654,457
Granted
Oct 14, 2025
Kind
B2
Abstract

A method of treating ocular pain or discomfort, the method comprising: administering to an eye of a subject suffering from or at risk of suffering from ocular pain or discomfort, a therapeutically effective amount of chondroitin sulfate at a concentration of 0.1% to 2.5% wt/wt.

Claims (10)

1. A method of treating ocular pain or discomfort, the method comprising: topically administering eye drops to an eye of a subject suffering from ocular pain or discomfort from ocular injury or an ocular surface disease, the eye drops comprising a therapeutically effective amount of chondroitin sulfate at a concentration from 0.1% to 2.5% wt/wt, wherein the eye drops have a viscosity about equal to water.

2. The method of claim 1 , wherein the eye drops are administered after the subject has undergone ocular surgery.

3. The method of claim 2 , wherein the ocular surgery is cataract surgery or refractive surgery.

4. The method of claim 2 , wherein the subject is suffering from surgical temporary ocular discomfort syndrome (STODS).

5. The method of claim 1 , wherein the ocular surface disease is selected from the group consisting of dry eye disease, contact lens induced ocular surface dry eye disease, and preservative induced ocular surface disease.

6. The method of claim 1 , wherein the eye drops are administered over at least 7 days, optionally for 14 days or more.

7. The method of claim 1 , wherein the eye drops are free of corticosteroids.

8. The method of claim 1 , wherein the chondroitin sulfate is provided at a concentration of 0.1% to 1.0% wt/wt.

9. The method of claim 1 , wherein the subject is suffering from corneal abrasion.

10. The method of claim 1 , wherein the ocular injury is from contact lens wear.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: LINDSTROM, RICHARD L.; HOSSEINI, KAMRAN; BOWMAN, LYLE
To: SURFACE OPHTHALMICS, INC.
Reel/Frame 067674/0822 →
Continuity (3)
Continuation In Part 18555982
Provisional Application 63186747 · May 10, 2021
Related Publication 20240285675A1 · Aug 29, 2024
References Cited (111)
US 4486416A · Soll et al. · 1984 [cited by applicant]
US 5514686A · Mochizuki et al. · 1996 [cited by applicant]
US 5518732A · Nigam · 1996 [cited by applicant]
US 6051560A · Chang et al. · 2000 [cited by applicant]
US 6489335B2 · Peyman · 2002 [cited by applicant]
US 6579901B2 · Chen et al. · 2003 [cited by applicant]
US 6878694B2 · Doshi et al. · 2005 [cited by applicant]
US 7083803B2 · Peyman · 2006 [cited by applicant]
US 7087237B2 · Peyman · 2006 [cited by applicant]
US 7335682B2 · Chen et al. · 2008 [cited by applicant]
US 7820639B2 · Lindstrom · 2010 [cited by applicant]
US 8551974B1 · Lindstrom · 2013 [cited by applicant]
US 8574562B2 · Goebel · 2013 [cited by applicant]
US 8663716B2 · Wada et al. · 2014 [cited by applicant]
US 9034843B2 · Matsumura et al. · 2015 [cited by applicant]
US 9233123B1 · Lindstrom · 2016 [cited by applicant]
US 9549966B2 · Hamrah et al. · 2017 [cited by applicant]
US 9572800B2 · Zarnitsyn et al. · 2017 [cited by applicant]
US 9789080B2 · Hou et al. · 2017 [cited by applicant]
US 10058616B2 · Hong et al. · 2018 [cited by applicant]
US 10201548B2 · Bowman et al. · 2019 [cited by applicant]
US 10206944B2 · De Rosa et al. · 2019 [cited by applicant]
US 10420796B2 · Funayama et al. · 2019 [cited by applicant]
US 10507230B2 · Yamamoto et al. · 2019 [cited by applicant]
US 10555947B2 · Musunuri et al. · 2020 [cited by applicant]
US 10588913B2 · Tada et al. · 2020 [cited by applicant]
US 10716804B2 · Funayama · 2020 [cited by applicant]
US 11207345B2 · Funayama et al. · 2021 [cited by applicant]
US 11766421B2 · Saadeh et al. · 2023 [cited by applicant]
US 20010041671A1 · Napoli · 2001 [cited by applicant]
US 20030130301A1 · Ueno · 2003 [cited by applicant]
US 20050063996A1 · Peyman · 2005 [cited by applicant]
US 20060110459A1 · Jafari et al. · 2006 [cited by applicant]
US 20060148686A1 · Xia et al. · 2006 [cited by applicant]
US 20070082841A1 · Higuchi et al. · 2007 [cited by applicant]
US 20070259021A1 · Friedlaender et al. · 2007 [cited by applicant]
US 20070280924A1 · Daniels et al. · 2007 [cited by applicant]
US 20080242646A1 · Lessem et al. · 2008 [cited by applicant]
US 20100010082A1 · Chong et al. · 2010 [cited by applicant]
US 20100286065A1 · Lambert et al. · 2010 [cited by applicant]
US 20140031298A1 · Hughes et al. · 2014 [cited by applicant]
US 20170161438A1 · Connery et al. · 2017 [cited by applicant]
US 20180117064A1 · Tada et al. · 2018 [cited by applicant]
US 20190008920A1 · Arumugham et al. · 2019 [cited by applicant]
US 20190151338A1 · Saadeh · 2019 [cited by applicant]
US 20190298738A1 · Bowman et al. · 2019 [cited by applicant]
US 20190332516A1 · Bowman et al. · 2019 [cited by applicant]
US 20200129526A1 · Tada et al. · 2020 [cited by applicant]
US 20200171075A1 · Friedman · 2020 [cited by applicant]
US 20220071945A1 · Hosseini et al. · 2022 [cited by applicant]
US 20220143075A1 · Saadeh et al. · 2022 [cited by applicant]
US 20230277557A1 · Sternberg et al. · 2023 [cited by applicant]
US 20240207305A1 · Lindstrom et al. · 2024 [cited by applicant]
CN 1317342A · 2001 [cited by applicant]
CN 10299029A · 2011 [cited by applicant]
CN 111991415A · 2020 [cited by examiner]
EP 0063973B1 · 1984 [cited by applicant]
EP 0167363B1 · 1990 [cited by applicant]
EP 0232377B1 · 1990 [cited by applicant]
EP 0517972B1 · 1995 [cited by applicant]
EP 1188434B1 · 2006 [cited by applicant]
EP 2560616B1 · 2011 [cited by applicant]
EP 1948131B3 · 2013 [cited by applicant]
EP 2946782B1 · 2013 [cited by applicant]
EP 2937088B1 · 2013 [cited by applicant]
EP 1173177B2 · 2014 [cited by applicant]
EP 2979689A1 · 2016 [cited by applicant]
EP 2493942B1 · 2016 [cited by applicant]
EP 3409292B1 · 2018 [cited by applicant]
EP 4088757A1 · 2021 [cited by applicant]
EP 2695621B1 · 2021 [cited by applicant]
EP 3023108B1 · 2021 [cited by applicant]
EP 3831394A1 · 2021 [cited by applicant]
JP 2005289900A · 2005 [cited by examiner]
JP 200986619A · 2009 [cited by applicant]
JP 2016050181A · 2016 [cited by applicant]
JP 2016188237A · 2016 [cited by applicant]
JP 2017206547A · 2017 [cited by applicant]
JP 201883805A · 2018 [cited by applicant]
JP 2018203792A · 2018 [cited by applicant]
JP 2019182825A · 2019 [cited by applicant]
JP 2019199469A · 2019 [cited by applicant]
JP 2020138928A · 2020 [cited by applicant]
JP 202175531A · 2021 [cited by applicant]
JP 2022157707A · 2022 [cited by applicant]
WO 9625145A1 · 1996 [cited by applicant]
WO 2006073786A2 · 2004 [cited by applicant]
WO 2005030205A1 · 2005 [cited by applicant]
WO 2006044155A2 · 2006 [cited by applicant]
WO 2007092620A2 · 2007 [cited by applicant]
WO 2018104950A1 · 2018 [cited by applicant]
WO 2018114557A1 · 2018 [cited by applicant]
WO 2018212846A1 · 2018 [cited by applicant]
WO 2019060696A1 · 2019 [cited by applicant]
WO 2017040099A1 · 2019 [cited by applicant]
WO 2019216381A1 · 2019 [cited by applicant]
WO 2020106337A1 · 2020 [cited by applicant]
WO 2020139525A1 · 2020 [cited by applicant]
WO 2022076398 · 2022 [cited by applicant]
WO 2023141334A2 · 2023 [cited by applicant]
Hirabayashi MT, Barnett BP. Solving STODS—Surgical Temporary Ocular Discomfort Syndrome. Diagnostics (Basel). 2023;13(5): 837. (Year: 2023). [cited by examiner]
Vichyanond et al. “Use of Cyclosporine A and Tacrolimus in Treatment of Vernal Keratoconjunctivitis” Curr Allergy Asthma Rep, (2013) 13:308-314. [cited by applicant]
Bhatti et al. “Severe acute fibrinous and organzing pneumonia (AFOP) causing ventilatory failure: Successful treatment with mycophenolate mofetil and corticosteroids”, Respiratory Medicine (2009) 13:1764-1767. [cited by applicant]
Dogru et al., “Pharmacotherapy of dry eye”, Epert Opin. Pharmacother. (2011)12(3):325-334. [cited by applicant]
Gipson et al., “Clinical trial of focal segmental glomerulosclerosis in children and young adults”, Kidney International (2011) 80:868-878. [cited by applicant]
Gumus et al., “The role of inflammation and antiinflammation therapies in keratoconjunctivitis sica”, Clinical Ophthamology (2009) 3:57-67. [cited by applicant]
Vickers et al., “The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline”, Ophthalmol Ther (2015) 4:69-78. [cited by applicant]
Matossian et al., Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Opthalmic Emulsion, Clinical Opthalmology (2021)15:1979-1984. [cited by applicant]
Mueller et al., “Refractive Surgery Alliance Issues Updated Nomenclature Recommendations”, Opthalmology Advisor Opinion, https://www.ophthalmologyadvisor.com/topics/practice-management/refractive-surgery-alliance-offers… [cited by applicant]
PCT/US2022/027177 International Search Report and Written Opinion mailed Jul. 25, 2022. [cited by applicant]
Limberg et al., “Topical Application of Hyaluronic Acid and Chondroitin Sulfate in the Treatment of Dry Eyes”, American Journal of Ophthalmology, (1987) 103(2):194-197. [cited by applicant]